Co-loading of the anti-PD-L1 antibody provides MNPs with favorable tumor targeting and permeating properties and enhances their ability to inhibit the growth of primary breast cancer, while CS modification promotes their accumulation at the tumor site. Here, CD274 is linked to breast cancer.